SCHEMBL13726313

SCHEMBL13726313

c1ccc(-c2nc3ccccc3nc2-c2ccc(-c3cccc4c(-c5cccnc5)cccc34)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.54
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
TNF P01375 1/20 0.51
DHODH Q02127 1/20 0.48
MAPK1 P28482 1/20 0.48
CLK1 P49759 1/20 0.48
LMNA P02545 3/20 0.47
KDM4E B2RXH2 3/20 0.47
GAA P10253 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 5/20 0.47
HPGD P15428 3/20 0.47
F2 P00734 1/20 0.47
DHPS P49366 1/20 0.46
CYP1A2 P05177 3/20 0.46
CYP3A4 P08684 3/20 0.46
CLK4 Q9HAZ1 3/20 0.46
CYP2D6 P10635 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29412316 1.00 CYP11B1 (0.54) CYP11B1MEN1KMT2AL3MBTL1TNF
SCHEMBL13727179 0.98 CYP11B1 (0.55) CYP11B1MEN1KMT2AL3MBTL1TNF
SCHEMBL29412310 0.95 CYP11B1 (0.55) CYP11B1MEN1KMT2AL3MBTL1TNF
SCHEMBL13727213 0.95 CYP11B1 (0.55) CYP11B1MEN1KMT2AL3MBTL1TNF
SCHEMBL24433143 0.94 CYP11B1 (0.49) CYP11B1MEN1KMT2AL3MBTL1TNF
SCHEMBL13725983 0.94 L3MBTL1 (0.55) CYP11B1MEN1KMT2AL3MBTL1TNF
SCHEMBL13726849 0.94 CYP11B1 (0.57) CYP11B1MEN1KMT2AL3MBTL1DHODH
SCHEMBL13727203 0.93 DHODH (0.48) CYP11B1MEN1KMT2AL3MBTL1TNF
SCHEMBL13726693 0.93 L3MBTL1 (0.54) CYP11B1MEN1KMT2AL3MBTL1TNF
SCHEMBL13727511 0.91 L3MBTL1 (0.53) CYP11B1MEN1KMT2AL3MBTL1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065378-B1 Quinoxaline derivate, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative SEMICONDUCTOR ENERGY LAB (JP) 2015-01-28 EP disclosed
US-8586740-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-11-19 US disclosed
US-20130049577-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2013-02-28 US disclosed
US-20130049577-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2013-02-28 US disclosed
US-8314101-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-11-20 US disclosed
US-20090203704-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-08-13 US disclosed
US-20090203704-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203704-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative PDXK, NQO1, PPOX CYP11B1 2804/4885MEN1 1618/4885KMT2A 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.